NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that it has entered a collaboration with Five Prime Therapeutics to develop a blood-based companion diagnostic assay for use with Five Prime's investigational drug candidate, bemarituzumab.

Under the agreement, PGDx is creating and validating a circulating tumor DNA test to identify the approximately 10 percent of gastric and gastroesophageal junction cancer patients whose tumors are FGFR2 gene-amplified and therefore eligible for treatment with the drug.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.